Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined, these ...
News-Medical.Net on MSN
Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer
A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...
As reviewed above, much has been learned over the past 20 years regarding the pathways that KRAS engages and requires during lung tumorigenesis, and specific inhibitors of these downstream signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback